The importance of potency and durability in HIV patient antiretroviral therapy preferences: A telephone survey

AIDS Patient Care and STDs

Volumn 19, Issue 12, 2005, Pages 794-802

  Sherer Jr , Renslow D ^a,d   Fath, Michael J ^b   Da Silva, Barbara A ^b   Nicolau, Ana Maria ^b   Miller, Nancy L ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b ABBOTT LABORATORIES   (United States)

^c Johnston Zabor McManus Inc   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG POTENCY; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH SURVEY; HIGH RISK BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; RATING SCALE; REVIEW; SEROCONVERSION; SIDE EFFECT; TELEPHONE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE SURVEYS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; REVERSE TRANSCRIPTASE INHIBITORS; TELEPHONE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 30744467401     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2005.19.794     Document Type: Review

References (20)

1. Stone V, Jordan J, Tolson J, Pilon T. Potential impact of once daily regimens on adherence to HAART. 40th Infectious Disease Society of America. Chicago, 2002.
2. Murphy D, Roberts K, Marin D, Marelich W, Huffman D. Barriers to antiretroviral adherence among HIV-infected adults. AIDS Patient Care STDs 2000; 14:47-58.
3. Gallant J, Block D. Adherence to antiretroviral regimens in HIV-infected patients: Results of a survey among physicians and patients. J Int Assoc Physicians AIDS Care 1998;4:32-35.
4. Moyle G. The APPT-1 Study: Assessing Patients' Preferred Treatments. 6th International Congress on Drug Therapy in HIV-infection. Glasgow, Scotland, 2002.
5. Moyle G. The Assessing Patients' Preferred Treatments (APPT-1) study. Int J STD AIDS 2003;14:34-36.
6. Bass D, Smith M. HIV patients prefer once-daily regimens. 14th World AIDS Conference. Barcelona, Spain, 2002.
7. Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence in HIV medication regimens: A review of published and abstract reports. Patient Educ Couns 2002;46:93-108.
8. Ena J, Pasquau F. Once-a-day highly active antiretroviral therapy: A systematic review. Clin Infect Dis 2003;36:1186-1190.
9. Gathe J, Podzamczer D, Johnson M, et al. Once-daily vs. twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 48-week results. 11th Conference on Retrovirus and Opportunistic Infections [Poster 570]. San Francisco, February 8-11, 2004.
10. Stone V. Strategies for optimizing adherence to highly active antiretroviral therapy: Lessons from research and clinical practice. Clin Infect Dis 2001;33:865-872.
11. Miller L, Huffman H, Weidmer B, Hays R. Patient preferences regarding antiretroviral therapy. Intl J STD AIDS 2002;13:593-601.
12. Ickovics J, Meade C. Adherence to antiretroviral therapy among patients with HIV: A critical link between behavioral and biomedical sciences. J Acquir Immune Defic Syndr 2002;31:S98-S102.
13. Raboud J, Harris M, Rae S, Montaner JSG. Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy. HIV Med 2002;3:118.
14. de Olalla G, Knobel H, Carmona A, Guelar A, Lopez-Colomes J, Cayla J. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30:105-110.
15. Ostrow D, Fox K, Kleeberger, C, et al. Psychosocial Correlates of Incomplete Adherence to HIV Antiretroviral Therapy (HAART): Mental Health Matters [Poster #484]. 8th Conference on Retrovirus and Opportunistic Infections. Chicago, 2001.
16. Ruhnke G, Wilson S, Akamatsu T, et al. Ethical decision making and patient autonomy. A comparison of physicians and patients in Japan and the United States. Chest 2000;118:1172-1182.
17. Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti J. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: From a predictive to a dynamic approach. Soc Sci Med 2002;54: 1481-1496.
18. Hill Z, Kendall C, Fernandez M. Patterns of adherence to antiretrovirals: Why adherence has no simple measure. AIDS Patient Care STDs 2003;17:519-525.
19. Mostashari F, Riley E, Selwyn P, Altice F. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility. J Acquir Immune Defic Syndr 1998;18:341-348.
20. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, aidsinfo.nih.gov/guidelines/ (Last accessed October 29, 2004).